
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934**

For the month of June, 2022

Commission File Number 001-39670

PURETECH HEALTH PLC

(Translation of registrant's name into English)

**6 Tide Street, Suite 400
Boston, Massachusetts 02210**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a \$50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches. In respect of the first tranche, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than \$25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the first tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on May 27, 2021, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended June 30, 2022, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:

| <u>Date</u> | <u>Ordinary Shares Repurchased</u> | <u>Volume Weighted Average Price Paid per Ordinary Share</u> | <u>Highest Price Paid</u> | <u>Lowest Price Paid</u> |
|---------------|------------------------------------|--|---------------------------|--------------------------|
| June 1, 2022 | 50,156 | 179.20p | 181.00p | 175.20p |
| June 6, 2022 | 46,779 | 181.60p | 187.00p | 177.40p |
| June 7, 2022 | 46,350 | 175.99p | 180.40p | 173.00p |
| June 8, 2022 | 44,526 | 181.47p | 185.80p | 175.60p |
| June 9, 2022 | 46,602 | 181.14p | 184.20p | 178.20p |
| June 10, 2022 | 46,606 | 173.05p | 178.40p | 169.80p |
| June 13, 2022 | 50,508 | 163.77p | 166.00p | 161.00p |
| June 14, 2022 | 56,309 | 159.90p | 164.20p | 155.80p |
| June 15, 2022 | 58,827 | 157.18p | 159.20p | 155.60p |
| June 16, 2022 | 61,103 | 153.34p | 157.20p | 150.00p |
| June 17, 2022 | 65,330 | 156.03p | 160.40p | 150.00p |
| June 20, 2022 | 43,188 | 157.13p | 163.00p | 149.40p |
| June 21, 2022 | 35,858 | 162.79p | 162.80p | 162.20p |
| June 22, 2022 | 108,930 | 159.72p | 164.00p | 156.60p |
| June 23, 2022 | 120,037 | 161.35p | 163.80p | 159.00p |
| June 24, 2022 | 79,353 | 166.16p | 166.60p | 164.40p |
| June 27, 2022 | 30,770 | 170.25p | 170.40p | 166.00p |
| June 28, 2022 | 3,432 | 171.60p | 171.60p | 171.60p |
| June 29, 2022 | 131,279 | 168.16p | 171.40p | 165.20p |
| June 30, 2022 | 141,210 | 170.72p | 173.80p | 167.20p |

During the month ended June 30, 2022, the Company repurchased an aggregate of 1,267,153 Ordinary Shares. As of June 30, 2022, the Company’s issued share capital was 288,611,120 shares, 2,010,269 of which were held in treasury, resulting in total voting rights in the Company of 286,600,851 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

June 1, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4394137.html>

June 6, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4394394.html>
June 7, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4395829.html>
June 8, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4397643.html>
June 9, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4399229.html>
June 10, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4400772.html>
June 13, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4402580.html>
June 14, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4404024.html>
June 15, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4405896.html>
June 16, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4407371.html>
June 17, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4409107.html>
June 20, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4410787.html>
June 21, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4412925.html>
June 22, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4414074.html>
June 23, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4415721.html>
June 24, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4417224.html>
June 27, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4418886.html>
June 28, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4420771.html>
June 29, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4422525.html>
June 30, 2022: <https://data.fca.org.uk/artefacts/NSM/RNS/4424516.html>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PURETECH HEALTH PLC

Date: July 5, 2022

By: /s/ Daphne Zohar

Name: Daphne Zohar

Title: Chief Executive Officer